{
    "Clinical Trial ID": "NCT00245050",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Pyridoxine",
        "  Arm I: Patients receive doxorubicin HCl liposome IV 40mg/m2 over 1 hour on day 1 and oral pyridoxine 100 mg twice daily on days 1-28.",
        "INTERVENTION 2: ",
        "  Placebo",
        "  Arm II: Patients receive doxorubicin HCl liposome IV 40mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28."
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Diagnosis of 1 of the following:",
        "  Recurrent ovarian, fallopian tube, or peritoneal cavity cancer",
        "  Metastatic breast cancer",
        "  Advanced endometrial cancer",
        "  Planning to receive chemotherapy with doxorubicin HCl liposome at a dose of 40 mg/m^2",
        "  Hormone receptor status:",
        "  Not specified",
        "  PATIENT CHARACTERISTICS:",
        "  Sex",
        "  Not specified",
        "  Menopausal status:",
        "  Not specified",
        "  Performance status",
        "  Karnofsky 60-100%",
        "  Life expectancy",
        "  Not specified",
        "  Hematopoietic",
        "  Absolute neutrophil count  1,500/mm^3",
        "  Platelet count  100,000/mm^3",
        "  Hemoglobin  9.0 g/dL",
        "  Hepatic",
        "  AST and ALT  2 times upper limit of normal (ULN)",
        "  Alkaline phosphatase  2 times ULN",
        "  Bilirubin normal",
        "  Renal",
        "  Creatinine  2.0 mg/dL",
        "  Cardiovascular",
        "  Ejection fraction  50% by MUGA or 2-D echocardiogram",
        "  No history of cardiac disease",
        "  No New York Heart Association class II-IV heart disease",
        "  No clinical evidence of congestive heart failure",
        "  Other",
        "  Not pregnant or nursing",
        "  Fertile patients must use effective contraception during and for 3 months after completion of study treatment",
        "  No active infection requiring antibiotics",
        "  No history of hypersensitivity reaction attributed to a conventional formulation of doxorubicin HCl or doxorubicin HCl liposome and any of its components",
        "  No other invasive malignancy within the past 5 years except nonmelanoma or basal cell skin cancer",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy",
        "  At least 3 weeks since prior biologic or immunologic agents for this cancer",
        "  Chemotherapy",
        "  Recovered from prior chemotherapy",
        "  Alopecia or neuropathy allowed",
        "  No prior doxorubicin HCl liposome",
        "  Other concurrent chemotherapy allowed provided palmar-plantar erythrodysesthesia is not one of the side effects of the therapy",
        "  No concurrent cytarabine, fluorouracil, liposomal daunorubicin, or capecitabine",
        "  No concurrent pre-medication with corticosteroids as part of the chemotherapy regimen",
        "  Endocrine therapy",
        "  See Chemotherapy",
        "  At least 3 weeks since prior and no concurrent oral or topical corticosteroids",
        "  At least 1 week since prior hormonal therapy for this cancer",
        "  Concurrent hormone replacement therapy allowed",
        "  Radiotherapy",
        "  At least 3 weeks since prior radiotherapy for this cancer and recovered",
        "  Surgery",
        "  Recovered from prior surgery",
        "  Other",
        "  At least 3 weeks since prior and no other concurrent forms of pyridoxine except what is included in a multivitamin",
        "  No prior anticancer treatment that contraindicates study treatment",
        "  No concurrent amifostine or other protective agents"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With Palmar-plantar Erythrodysesthesia (PPE)",
        "  Patients were monitored weekly with phone calls from the research nurse and monthly at clinic visits for overall (including pyridoxine) and specific doxorubicin HCl liposome related toxicities using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.",
        "  Time frame: Treatment repeats every 4 weeks for up to 6 courses in the absence of unacceptable toxicity.",
        "Results 1: ",
        "  Arm/Group Title: Pyridoxine",
        "  Arm/Group Description: Arm I: Patients receive doxorubicin HCl liposome IV 40mg/m2 over 1 hour on day 1 and oral pyridoxine 100 mg twice daily on days 1-28.",
        "  Overall Number of Participants Analyzed: 15",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Grade 1 HFS: 2",
        "  Grade 2 HFS: 3",
        "Grade 3 HFS: 3",
        "Results 2: ",
        "  Arm/Group Title: Placebo",
        "  Arm/Group Description: Arm II: Patients receive doxorubicin HCl liposome IV 40mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.",
        "  Overall Number of Participants Analyzed: 14",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Grade 1 HFS: 3",
        "  Grade 2 HFS: 3",
        "Grade 3 HFS: 1"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 8/15 (53.33%)",
        "  Blood/bone marrow  1/15 (6.67%)",
        "  Hemorrhage/bleeding  1/15 (6.67%)",
        "  Lymphatics  0/15 (0.00%)",
        "  Gastrointestinal  2/15 (13.33%)",
        "  Constitutional symptoms  0/15 (0.00%)",
        "  Pain  0/15 (0.00%)",
        "  Allergy/immunologic  0/15 (0.00%)",
        "  Infection  1/15 (6.67%)",
        "  Metabolic/laboratory  0/15 (0.00%)",
        "  Neurology  1/15 (6.67%)",
        "  Renal/genitourinary  0/15 (0.00%)",
        "Adverse Events 2:",
        "  Total: 6/14 (42.86%)",
        "  Blood/bone marrow  2/14 (14.29%)",
        "  Hemorrhage/bleeding  0/14 (0.00%)",
        "  Lymphatics  0/14 (0.00%)",
        "  Gastrointestinal  0/14 (0.00%)",
        "  Constitutional symptoms  1/14 (7.14%)",
        "  Pain  0/14 (0.00%)",
        "  Allergy/immunologic  1/14 (7.14%)",
        "  Infection  0/14 (0.00%)",
        "  Metabolic/laboratory  1/14 (7.14%)",
        "  Neurology  0/14 (0.00%)",
        "  Renal/genitourinary  0/14 (0.00%)"
    ]
}